BPG is committed to discovery and dissemination of knowledge
Home / Archive / Volume 20, Issue 11
  • This Article
Peer-Review Report of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight
©2014 Baishideng Publishing Group Co.
World J Gastroenterol. Mar 21, 2014; 20(11): 2867-2875
Published online Mar 21, 2014. doi: 10.3748/wjg.v20.i11.2867
Table 1 New drugs for treating chronic hepatitis C
ClassDrugPhase of study
NS3/4A protease inhibitorsTelaprevirApproved
BoceprevirApproved
SimeprevirIII
FaldaprevirIII
DanoprevirII
VaniprevirII
NarlaprevirII
AsunaprevirII
GS-9256II
GW-9451II
ABT-450/rII
ACH-1625II
ACH-2684Ib
MK-5172II
Nucleoside/nucleotide analogue inhibitors of HCV-RNA dependent RNA polymeraseSofosbuvirIII
MericitabineII
IDX184II
PSI-938II
INX-189Ib
Non-nucleoside inhibitors of HCV-RNA dependent RNA polymeraseTegobuvirII
FilibuvirII
SetrobuvirII
BI207127II
ABT-333II
VX-222II
TMC-647055Ib
NS5A inhibitors of HCV-RNA dependent RNA polymeraseDaclatasvirII
PPI-461Ib
GS-5885Ib
GSK2336805Ib
Cyclophilin inhibitorsAlisporivirIII
SCY-465II
Adapted from Pawlotsky et al[50]. HCV: Hepatitis C virus.
Full Size Table
Write to the Help Desk
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.